AFT Pharmaceuticals (ASX:AFP) Cash-to-Debt : 0.17 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AFT Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.17.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AFT Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for AFT Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ASX:AFP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.17 Max: No Debt
Current: 0.17

During the past 8 years, AFT Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 0.17.

ASX:AFP's Cash-to-Debt is ranked worse than
78.27% of 1049 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs ASX:AFP: 0.17

AFT Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for AFT Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AFT Pharmaceuticals Cash-to-Debt Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.17

0.13

0.08

0.20

0.13

AFT Pharmaceuticals Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial											0.14	0.20	No Debt	0.13	0.17

Competitive Comparison of AFT Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Cash-to-Debt falls into.

AFT Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AFT Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.416	/	(2.817	+	32.564)
	=	0.12

AFT Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.696	/	(0	+	33.797)
	=	0.17

AFT Pharmaceuticals (ASX:AFP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AFT Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (ASX:AFP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (ASX:AFP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.

AFT Pharmaceuticals (ASX:AFP) Headlines

No Headlines